BR9906821A - Pharmaceutical composition and process to improve levodopa-induced dyskinesia and tardive dyskinesia, and use of riluzole for the preparation of a pharmaceutical composition - Google Patents

Pharmaceutical composition and process to improve levodopa-induced dyskinesia and tardive dyskinesia, and use of riluzole for the preparation of a pharmaceutical composition

Info

Publication number
BR9906821A
BR9906821A BR9906821-4A BR9906821A BR9906821A BR 9906821 A BR9906821 A BR 9906821A BR 9906821 A BR9906821 A BR 9906821A BR 9906821 A BR9906821 A BR 9906821A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
dyskinesia
preparation
riluzole
induced
Prior art date
Application number
BR9906821-4A
Other languages
Portuguese (pt)
Inventor
Eldad Melamed
Ruth Djaldetti
Ilan Ziv
Original Assignee
Mor Research Applic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL12288398A external-priority patent/IL122883A0/en
Priority claimed from IL12710298A external-priority patent/IL127102A0/en
Application filed by Mor Research Applic Ltd filed Critical Mor Research Applic Ltd
Publication of BR9906821A publication Critical patent/BR9906821A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA E PROCESSO PARA MELHORAR A DISCINESIA INDUZIDA POR LEVODOPA E DISCINESIA TARDIA, E, USO DE RILUZOL PARA A PREPARAçãO DE UMA COMPOSIçãO FARMACêUTICA" Discinesia induzida por levodopa e discinesia tardia são melhoradas por administração de um riluzol a indivíduos em necessidade do mesmo."PHARMACEUTICAL COMPOSITION AND PROCESS TO IMPROVE LEVODOPA-INDUCED DYSKINESIA AND LATE DYSKINESIA, AND, USE OF RILUZOL FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION" Levodopa-induced dyskinesia and late dyskinesia are improved by the administration of a ril.

BR9906821-4A 1998-01-09 1999-01-05 Pharmaceutical composition and process to improve levodopa-induced dyskinesia and tardive dyskinesia, and use of riluzole for the preparation of a pharmaceutical composition BR9906821A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12288398A IL122883A0 (en) 1998-01-09 1998-01-09 Pharmaceutical compositions for the treatment of dyskinesias
IL12710298A IL127102A0 (en) 1998-11-17 1998-11-17 Pharmaceutical compositions for the treatment of dyskinesias
PCT/IL1999/000003 WO1999034785A2 (en) 1998-01-09 1999-01-05 Treatment of dyskinesias

Publications (1)

Publication Number Publication Date
BR9906821A true BR9906821A (en) 2000-10-17

Family

ID=26323572

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9906821-4A BR9906821A (en) 1998-01-09 1999-01-05 Pharmaceutical composition and process to improve levodopa-induced dyskinesia and tardive dyskinesia, and use of riluzole for the preparation of a pharmaceutical composition

Country Status (10)

Country Link
EP (1) EP1043996A2 (en)
JP (1) JP2002500181A (en)
KR (1) KR20010033978A (en)
CN (1) CN1290166A (en)
AU (1) AU1780699A (en)
BR (1) BR9906821A (en)
CA (1) CA2317811A1 (en)
NO (1) NO20003529L (en)
PL (1) PL342098A1 (en)
WO (1) WO1999034785A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1161238A1 (en) * 1999-03-12 2001-12-12 Aventis Pharma S.A. Amyotropic lateral sclerosis treatment with a combination of riluzole and an ampa receptor antagonist
FR2790670A1 (en) * 1999-03-12 2000-09-15 Aventis Pharma Sa Treatment or prevention of amyotrophic lateral sclerosis, using synergistic combination of riluzole and AMPA receptor antagonist, e.g. 5H,10H-imidazo (1,2-a) indeno (1,2-e) pyrazin-4-one derivative
FR2801793B1 (en) * 1999-12-01 2003-07-04 Aventis Pharma Sa COMBINATION OF ERGOLIN AND RILUZOLE AND ITS USE AS A MEDICINAL PRODUCT
US6297254B1 (en) 1999-12-01 2001-10-02 Aventis Pharma S. A. Method for the prevention or treatment of a motoneuron disease
FR2809620B1 (en) * 2000-06-05 2002-08-02 Aventis Pharma Sa USE OF RILUZOLE OR ITS SALTS FOR THE PREVENTION AND TREATMENT OF ADRENOLEUCODYSTROPHY
DE60100595T2 (en) * 2001-05-08 2004-06-24 Lts Lohmann Therapie-Systeme Ag Improved transdermal therapeutic system for the treatment of Parkinson's disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688138B1 (en) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa APPLICATION OF AMINO-2 TRIFLUOROMETHOXY-6 BENZOTHIAZOLE TO OBTAIN A MEDICINE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.
FR2700117B1 (en) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application of anti-convulsants in the treatment of Parkinson's disease and parkinsonian syndromes.

Also Published As

Publication number Publication date
PL342098A1 (en) 2001-05-21
AU1780699A (en) 1999-07-26
CA2317811A1 (en) 1999-07-15
NO20003529D0 (en) 2000-07-07
JP2002500181A (en) 2002-01-08
CN1290166A (en) 2001-04-04
WO1999034785A3 (en) 1999-09-16
NO20003529L (en) 2000-09-08
WO1999034785A2 (en) 1999-07-15
EP1043996A2 (en) 2000-10-18
KR20010033978A (en) 2001-04-25

Similar Documents

Publication Publication Date Title
BR9909329A (en) Method for stabilizing pharmaceutical compositions by special use of an antioxidant
BR9610838A (en) Process for treating an individual having a pathological condition involving neovascularization.
HK1077208A1 (en) Topical composition containing at least one vitminD or one vitamin D analogue and at least one cort icosteroid
BR9903984B1 (en) A process for producing an aqueous composition containing a pharmaceutically effective peptide.
GT199800197AA (en) PROCESS FOR THE SYNTHESIS OF 1,3-DIOLES
BR9906088A (en) Valve for actuation of pneumatic cylinders in general
DK0915898T3 (en) Crystal form I of clarithromycin
CY1112139T1 (en) A PHARMACEUTICAL COMPOSITION INCLUDING CRYSTALL RITONAVIR FORM II AND A PREPARATION THEREOF
BR9801606B1 (en) compound, process for its preparation, pharmaceutical substance, use of the compound and process for the production of a pharmaceutical substance.
BR9404330A (en) Device for mixing a pharmaceutical composition with another agent, process for preparing a pharmaceutical preparation by mixing a pharmaceutical composition with an agent, and process for the oral application of a pharmaceutical preparation.
BR9813378A (en) Compound, process for preparing the same, and use of it, pharmaceutical composition, and process for preparing the same, and process for effecting immunosuppression
BR0116698A (en) Modafinil compound and cyclodextrin mixtures, use and method of obtaining them
BR9906070A (en) Substituted benzamides
DE69912983D1 (en) WATER MIXABLE PHARMACEUTICAL COMPOSITIONS CONTAINING PACLITAXEL
BR0107899A (en) Process for producing an active ingredient preparation comprising ibuprofen, preparation of active ingredient, use thereof, pharmaceutical preparation, use thereof, process for producing solid dosage forms, and, solid dosage form
BR9906821A (en) Pharmaceutical composition and process to improve levodopa-induced dyskinesia and tardive dyskinesia, and use of riluzole for the preparation of a pharmaceutical composition
BRPI9914571B1 (en) compound, process for its preparation, use thereof, as well as pharmaceutical composition.
BR9713159A (en) Substantially solid composition, compound, substantially solid salt composition, mixture, and, process for preparing a compound
BR9602025A (en) Compound use, pharmaceutical composition and process for the preparation of a compound
BR9814495A (en) Compound, process to prepare it, use of it, pharmaceutical composition, and, process
BR9908195A (en) Derived from group b of streptogramins, process for preparing it, pharmaceutical compositions, and associations of streptogramin derivatives.
BR9507381A (en) Compound use of a compound process for the treatment of a manifest pharmaceutical composition and process for the preparation of compounds
BR9705456A (en) Heterocyclic compounds, aminomethyl process for their preparation and pharmaceutical compositions that contain them.
BR0309113A (en) Carbidopa and levodopa controlled release pharmaceutical compositions and processes for their preparation
BR9807785A (en) Process for the preparation of the compound, e, compound

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1910 DE 14/08/2007.